About PSI

On a daily basis, many individuals unknowingly risk death or serious injury to their health by taking counterfeit pharmaceuticals. Counterfeit products include drugs with no active ingredients to those with dangerous impurities. Counterfeit pharmaceuticals represent a serious threat to world health.

The Industry Response

In the late 1980’s, several major pharmaceutical companies found that the problem of counterfeiting of pharmaceutical products had reached a level where they needed to confront it together rather than separately. Glaxo, Bayer and Bristol-Myers Squibb were the first to come together, but soon other companies joined in the effort.

In late 2001, in response to the need to strengthen the anti-counterfeiting effort, a number of companies together founded the current PSI, a not-for-profit corporation based in the Washington, D.C. metropolitan area. Thomas T. Kubic, a respected law enforcement official with years of experience investigating sophisticated illegal activities worldwide, was recruited to serve as executive Director and took office on January 2, 2002. In September 2003, a PSI branch office was established in the London metropolitian area.

Representing pharmaceutical manufacturers from many nations, the PSI maintains a close affiliation with the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). The IFPMA Director-General serves as the PSI President.